EMEA-002350-PIP01-18

Key facts

Active substance
6-cyclopropaneamido-4-{[2-methoxy-3-(1-methyl-1H-1,2,4 triazol-3-yl)phenyl]amino}-N-(2H3)methylpyridazine-3-carboxamide (BMS-986165)
Therapeutic area
Dermatology
Decision number
P/0262/2019
PIP number
EMEA-002350-PIP01-18
Pharmaceutical form(s)
  • Film-coated tablet
  • Age-appropriate oral solid dosage form
Condition(s) / indication(s)
Treatment of psoriasis
Route(s) of administration
Oral use
Contact for public enquiries
Bristol-Myers Squibb International Corporation

Tel. +44 1895523740
E-mail: medical.information@bms.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating